Jill Ferdinands
Overview
Explore the profile of Jill Ferdinands including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Howa A, Zhu Y, Wyatt D, Markus T, Chappell J, Halasa N, et al.
J Infect Dis
. 2023 Sep;
229(6):1823-1829.
PMID: 37768170
Background: Influenza remains an important cause of hospitalizations in the United States. Estimating the number of influenza hospitalizations is vital for public health decision making. Combining existing surveillance systems through...
2.
Leis A, McSpadden E, Segaloff H, Lauring A, Cheng C, Petrie J, et al.
Influenza Other Respir Viruses
. 2023 Mar;
17(3):e13120.
PMID: 36909298
Background: Patients are admitted to the hospital for respiratory illness at different stages of their disease course. It is important to appropriately analyse this heterogeneity in surveillance data to accurately...
3.
Natarajan K, Prasad N, Dascomb K, Irving S, Yang D, Gaglani M, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Mar;
71(13):495-502.
PMID: 35358170
CDC recommends that all persons aged ≥18 years receive a single COVID-19 vaccine booster dose ≥2 months after receipt of an Ad.26.COV2.S (Janssen [Johnson & Johnson]) adenovirus vector-based primary series...
4.
Klein N, Stockwell M, Demarco M, Gaglani M, Kharbanda A, Irving S, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Mar;
71(9):352-358.
PMID: 35239634
The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data...
5.
Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Jan;
71(4):139-145.
PMID: 35085224
Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because of waning vaccine induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or...
6.
Embi P, Levy M, Naleway A, Patel P, Gaglani M, Natarajan K, et al.
Am J Transplant
. 2021 Dec;
22(1):306-314.
PMID: 34967121
No abstract available.
7.
Embi P, Levy M, Naleway A, Patel P, Gaglani M, Natarajan K, et al.
MMWR Morb Mortal Wkly Rep
. 2021 Nov;
70(44):1553-1559.
PMID: 34735426
Immunocompromised persons, defined as those with suppressed humoral or cellular immunity resulting from health conditions or medications, account for approximately 3% of the U.S. adult population (1). Immunocompromised adults are...
8.
Bozio C, Grannis S, Naleway A, Ong T, Butterfield K, DeSilva M, et al.
MMWR Morb Mortal Wkly Rep
. 2021 Nov;
70(44):1539-1544.
PMID: 34735425
Previous infection with SARS-CoV-2 (the virus that causes COVID-19) or COVID-19 vaccination can provide immunity and protection from subsequent SARS-CoV-2 infection and illness. CDC used data from the VISION Network*...
9.
Thompson M, Soto G, Peretz A, Newes-Adeyi G, Yoo Y, Hirsch A, et al.
Vaccine
. 2021 Sep;
39(47):6956-6967.
PMID: 34509322
Background: There are limited data on influenza vaccine effectiveness (IVE) in preventing laboratory-confirmed influenza illness among healthcare personnel (HCP). Methods: HCP with direct patient contact working full-time in hospitals were...
10.
Thompson M, Stenehjem E, Grannis S, Ball S, Naleway A, Ong T, et al.
N Engl J Med
. 2021 Sep;
385(15):1355-1371.
PMID: 34496194
Background: There are limited data on the effectiveness of the vaccines against symptomatic coronavirus disease 2019 (Covid-19) currently authorized in the United States with respect to hospitalization, admission to an...